Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2018 Publisher: Pfizer Limited, Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK
Synarel 2mg/ml Nasal Spray.
| Pharmaceutical Form |
|---|
|
Nasal spray, solution. Clear, colourless to slightly yellow, aqueous solution. |
Solution containing 2mg/ml of nafarelin (as acetate) supplied in bottles fitted with a metered spray pump that delivers 200 micrograms of nafarelin base per spray.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Nafarelin |
Nafarelin is a potent agonistic analogue of gonadotrophin releasing hormone (GnRH). Given as a single dose, nafarelin stimulates release of the pituitary gonadotrophins, LH and FSH, with consequent increase of ovarian and testicular steroidogenesis. |
| List of Excipients |
|---|
|
__Synarel contains:* Sorbitol |
White, high density polyethylene bottles with a 0.1ml metered spray pump, containing 6.5ml or 10ml.
PVC-coated glass bottles with an internal conical reservoir in the base and a valois pump, with either an aluminium crimp-on cap or a polypropylene snap-on cap, containing 4ml or 8ml.
Not all pack sizes may be marketed.
Pfizer Limited, Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK
PL 00057/1052
13 August 2003
| Drug | Countries | |
|---|---|---|
| SYNAREL | Australia, Canada, Spain, France, Ireland, Israel, Netherlands, Turkey, United Kingdom, United States |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
